用于治疗人类猴痘的特考韦瑞玛：来自美国马萨诸塞州的初始系列病例
Tecovirimat for the Treatment of Human Monkeypox: An Initial Series From Massachusetts, United States.
作者信息
Matias Wilfredo R, Koshy Jacob M, Nagami Ellen H, Kovac Victor, Moeng Letumile R, Shenoy Erica S, Hooper David C, Madoff Lawrence C, Barshak Miriam B, Johnson Jennifer A, Rowley Christopher F, Julg Boris, Hohmann Elizabeth L, Lazarus Jacob E
机构信息
Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Open Forum Infect Dis. 2022 Jul 27;9(8):ofac377. doi: 10.1093/ofid/ofac377. eCollection 2022 Aug.
A large, ongoing multicountry outbreak of human monkeypox has the potential to cause considerable morbidity and mortality. Therapeutics for the treatment of smallpox, a related , may be used and affect the natural history of monkeypox. We present 3 patients from our hospitals treated with tecovirimat, a pan- inhibitor currently available under an expanded access investigational new drug protocol for monkeypox.
一场大规模、持续的多国人间猴痘疫情有可能导致相当高的发病率和死亡率。治疗天花（一种相关疾病）的疗法可能会被使用，并影响猴痘的自然病程。我们介绍了来自我们医院的3例使用tecovirimat治疗的患者，tecovirimat是一种泛抑制剂，目前在一项针对猴痘的扩大准入研究性新药方案下可用。
Zotero 插件